Research-use context: This article is provided for laboratory research and educational purposes only. It is not medical, therapeutic, diagnostic, veterinary, dosing or human-use guidance.
A naming problem with scientific consequences
The term CJC-1295 is used inconsistently in the research-products market. The best-known published human study examined a long-acting GHRH analogue with drug-affinity-complex characteristics. Products described as “CJC-1295 No DAC” refer to a different molecular form and should not be assumed to share the same pharmacokinetic profile.
Do not collapse different forms into one evidence base
When reviewing literature, researchers should check exactly which molecular form was studied. A paper on long-acting CJC-1295 cannot automatically validate claims about a No-DAC material. This is a general lesson in peptide research: names are useful, but sequence and modification state define the analyte.
What documentation should show
For CJC-1295 No DAC research material, the product specification should state the intended form explicitly. Identity evidence should correspond to that form, and blend products should also document the second component separately where possible.
Reference
Teichman SL et al. J Clin Endocrinol Metab. 2006;91:799-805. PMID: 16352683.